XML 54 R41.htm IDEA: XBRL DOCUMENT
v3.10.0.1

INTANGIBLE ASSETS (Details Narrative) |  | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Jul. 31, 2018 USD ($) | Sep. 30, 2018 USD ($) Number | Sep. 30, 2017 USD ($) | Sep. 30, 2018 USD ($) Number | Sep. 30, 2017 USD ($)
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Amortization expense | $ |  | $ 31,100 | $ 18,433 | $ 77,123 | $ 52,321
Council License Agreement [Member] | Population Council, Inc. [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Milestone payments | $ |  |  |  | 20,000,000 |
Milestone payments payment after release of first commercial batch | $ |  |  |  | $ 20,000,000 |
Description of royalty payments |  |  |  | <p style="margin-top: 0pt; margin-bottom: 0pt"><font style="font: 10pt Times New Roman, Times, Serif">(i) if annual net sales are less than or equal to $50,000,000, a royalty of 5% of net sales; (ii) for annual net sales greater than $50,000,000 and less than or equal to $150,000,000, a royalty of 10% of such net sales; and (iii) for net sales greater than $150,000,000, a royalty of 15% of such net sales. The annual royalty rate will be reduced to 50% of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be reduced to 20% of the initial rate.</font></p> |
Council License Agreement [Member] | Knight Therapeutics Inc. [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Gross proceeds | $ | $ 50,000,000 |  |  |  |
Council License Agreement [Member] | Knight Therapeutics Inc. [Member] | Minimum [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Issue of common stock value | $ | $ 20,000,000 |  |  |  |
Approved Hormone Therapy Drug Candidate Patents [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Useful Life |  |  |  | 20 years |
Domestic U.S. Patents [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  | 20 |  | 20 |
Foreign Patents [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  | 22 |  | 22 |
Domestic Utility Patents [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  | 14 |  | 14 |
Domestic Patents - TX-004HR [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  | 3 |  | 3 |
Domestic Utility Patent - Pipeline Transdermal Patch Technology [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  | 1 |  | 1 |
Domestic Utilty Patent - Opera Software [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  | 1 |  | 1 |
Domestic Patents - TX-009HR [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  | 1 |  | 1 |

X
- Definition The description of royalty payments. + References No definition available. + Details
Name: | txmd_DescriptionOfRoyaltyPayments
Namespace Prefix: | txmd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of milestone payments. + References No definition available. + Details
Name: | txmd_MilestonePayments
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payments payment after release of first commercial batch. + References No definition available. + Details
Name: | txmd_MilestonePaymentsPaymentAfterReleaseOfFirstCommercialBatch
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of issued patents. + References No definition available. + Details
Name: | txmd_NumberOfIssuedPatents
Namespace Prefix: | txmd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References No definition available. + Details
Name: | txmd_ProceedsFromIssuanceOfCommonStock1
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=txmd_PopulationCouncilIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=txmd_KnightTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents5Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents4Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |